Share Price and Basic Stock Data
Last Updated: January 15, 2026, 3:53 am
| PEG Ratio | 5.39 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Solara Active Pharma Sciences Ltd, operating in the pharmaceutical industry, reported a market capitalization of ₹2,475 Cr, with a current stock price of ₹557. The company has experienced fluctuations in revenue, with total sales for the fiscal year ending March 2023 recorded at ₹1,444 Cr, a slight increase from ₹1,268 Cr in March 2022. However, sales have seen a decline in subsequent periods, with TTM sales standing at ₹1,206 Cr as of March 2025. Quarterly trends reveal that sales peaked at ₹425 Cr in September 2023 but dipped to ₹212 Cr in December 2023, indicating volatility. The operating profit margin (OPM) fluctuated significantly, recorded at 9% in September 2023, while the overall operating profit for March 2025 stood at ₹206 Cr, reflecting a recovery from a prior loss of ₹95 Cr in March 2024. Such trends highlight the company’s struggle with maintaining consistent revenue streams amidst competitive pressures in the pharmaceutical sector.
Profitability and Efficiency Metrics
Profitability metrics for Solara demonstrate a challenging landscape. The net profit for the fiscal year ending March 2025 was a mere ₹1 Cr, down from a net loss of ₹22 Cr in March 2023. The company’s return on equity (ROE) stood at a low 0.05%, reflecting poor shareholder returns compared to industry norms. The interest coverage ratio (ICR) was reported at 1.87x, indicating that the company barely meets its interest obligations, which raises concerns regarding financial stability. The cash conversion cycle (CCC) was recorded at 133 days, signaling inefficiencies in managing working capital, particularly when compared to more efficient players in the sector. Furthermore, the operating profit margin (OPM) displayed significant volatility, with a peak of 16.71% in March 2025, illustrating the company’s struggle to maintain profitability amidst rising operational costs.
Balance Sheet Strength and Financial Ratios
Solara’s balance sheet reflects a mixed picture of financial health. The company’s total borrowings stood at ₹646 Cr, with reserves amounting to ₹1,210 Cr, indicating a relatively leveraged position. The debt-to-equity ratio was reported at 0.70, which is elevated compared to industry averages, suggesting potential risks in financial management. The current ratio was recorded at 0.77, indicating a liquidity concern as it is below the ideal threshold of 1. The book value per share, inclusive of revaluation reserves, was ₹271.86 as of March 2025. In terms of efficiency, the return on capital employed (ROCE) was recorded at 6.01%, indicating that the company is generating a modest return on its capital investments. Overall, while Solara’s financial ratios reveal some strengths in its reserves, the high leverage and liquidity challenges present significant risks that could affect operational capabilities.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Solara reflects a diverse ownership structure, with promoters holding 42.01% of the total shares, a slight recovery from 30.49% in December 2023. Foreign Institutional Investors (FIIs) have reduced their stake to 13.58%, down from 19.26% in December 2022, indicating waning confidence among institutional investors. Domestic Institutional Investors (DIIs) hold 2.69%, while public shareholders account for 41.71%. The decline in FII participation may suggest concerns about the company’s financial performance and growth prospects. The total number of shareholders stood at 72,479, highlighting a broad base of retail investors. This diverse ownership can be a double-edged sword; while it provides stability, the declining institutional interest raises questions about long-term investor confidence in Solara’s strategic direction and financial recovery.
Outlook, Risks, and Final Insight
The outlook for Solara Active Pharma Sciences Ltd remains uncertain due to existing operational challenges and financial constraints. Key strengths include its significant reserves of ₹1,210 Cr and a recovery in operating profit margins, providing a foundation for potential growth. However, risks such as high debt levels, low ROE, and an inefficient cash conversion cycle could hinder recovery efforts. The company must address these operational inefficiencies and focus on enhancing profitability to restore investor confidence. In scenarios where Solara successfully streamlines operations and improves its financial metrics, it could witness a resurgence in both revenue and market sentiment. Conversely, failure to address these challenges may lead to continued volatility and diminished investor interest.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 130 Cr. | 103 | 208/84.3 | 28.7 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,079 Cr. | 374 | 479/192 | 84.5 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.3 Cr. | 44.8 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,219.23 Cr | 1,122.07 | 52.62 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 338 | 395 | 381 | 352 | 425 | 212 | 299 | 363 | 347 | 300 | 273 | 319 | 314 |
| Expenses | 311 | 350 | 332 | 333 | 388 | 374 | 290 | 322 | 286 | 243 | 228 | 262 | 279 |
| Operating Profit | 28 | 45 | 49 | 19 | 38 | -162 | 10 | 42 | 61 | 58 | 45 | 57 | 35 |
| OPM % | 8% | 11% | 13% | 5% | 9% | -76% | 3% | 12% | 18% | 19% | 17% | 18% | 11% |
| Other Income | 4 | 7 | 5 | 2 | -4 | -62 | -120 | 1 | 0 | 1 | 6 | 1 | 0 |
| Interest | 22 | 24 | 22 | 25 | 24 | 25 | 31 | 31 | 28 | 27 | 29 | 24 | 21 |
| Depreciation | 29 | 28 | 26 | 26 | 26 | 26 | 25 | 25 | 25 | 25 | 24 | 24 | 24 |
| Profit before tax | -19 | 1 | 5 | -29 | -17 | -275 | -167 | -13 | 8 | 8 | -2 | 11 | -10 |
| Tax % | -48% | 22% | 25% | -35% | 0% | 0% | 53% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -10 | 0 | 4 | -19 | -17 | -275 | -255 | -13 | 8 | 8 | -2 | 11 | -10 |
| EPS in Rs | -2.08 | 0.09 | 0.79 | -4.07 | -3.58 | -57.36 | -53.20 | -3.74 | 2.22 | 2.24 | -0.58 | 2.91 | -2.79 |
Last Updated: December 29, 2025, 2:32 am
Below is a detailed analysis of the quarterly data for Solara Active Pharma Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 314.00 Cr.. The value appears to be declining and may need further review. It has decreased from 319.00 Cr. (Jun 2025) to 314.00 Cr., marking a decrease of 5.00 Cr..
- For Expenses, as of Sep 2025, the value is 279.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 262.00 Cr. (Jun 2025) to 279.00 Cr., marking an increase of 17.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 57.00 Cr. (Jun 2025) to 35.00 Cr., marking a decrease of 22.00 Cr..
- For OPM %, as of Sep 2025, the value is 11.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Jun 2025) to 11.00%, marking a decrease of 7.00%.
- For Other Income, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Jun 2025) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 21.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 24.00 Cr. (Jun 2025) to 21.00 Cr., marking a decrease of 3.00 Cr..
- For Depreciation, as of Sep 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 24.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 11.00 Cr. (Jun 2025) to -10.00 Cr., marking a decrease of 21.00 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is -10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 11.00 Cr. (Jun 2025) to -10.00 Cr., marking a decrease of 21.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is -2.79. The value appears to be declining and may need further review. It has decreased from 2.91 (Jun 2025) to -2.79, marking a decrease of 5.70.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:37 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,206 |
| Expenses | 464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,384 | 1,077 | 1,011 |
| Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | -95 | 206 | 195 |
| OPM % | 11% | 15% | 20% | 24% | 6% | 9% | -7% | 16% | 16% |
| Other Income | 2 | 12 | 27 | 29 | 16 | 22 | -185 | 8 | 9 |
| Interest | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 115 | 100 |
| Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 99 | 97 |
| Profit before tax | 0 | 60 | 115 | 222 | -91 | -45 | -488 | 1 | 6 |
| Tax % | -70% | 1% | 0% | 0% | -36% | -50% | 16% | 0% | |
| Net Profit | 0 | 59 | 115 | 221 | -58 | -22 | -567 | 1 | 6 |
| EPS in Rs | 17.30 | 32.01 | 46.22 | -12.11 | -4.62 | -118.21 | 0.15 | 1.78 | |
| Dividend Payout % | 0% | 22% | 5% | 11% | 0% | -49% | 0% | 0% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 94.92% | 92.17% | -126.24% | 62.07% | -2477.27% | 100.18% |
| Change in YoY Net Profit Growth (%) | 0.00% | -2.74% | -218.42% | 188.31% | -2539.34% | 2577.45% |
Solara Active Pharma Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | 0% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -66% |
| 3 Years: | 26% |
| TTM: | 106% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | 18% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -4% |
| 3 Years: | -11% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 1:31 pm
Balance Sheet
Last Updated: December 4, 2025, 2:00 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 | 44 |
| Reserves | 739 | 930 | 1,059 | 1,553 | 1,489 | 1,464 | 898 | 1,054 | 1,210 |
| Borrowings | 633 | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 | 796 | 646 |
| Other Liabilities | 425 | 466 | 346 | 404 | 383 | 386 | 406 | 342 | 393 |
| Total Liabilities | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,293 |
| Fixed Assets | 1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,268 | 1,193 | 1,232 |
| CWIP | 71 | 40 | 40 | 88 | 239 | 238 | 256 | 280 | 230 |
| Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 |
| Other Assets | 663 | 701 | 716 | 1,144 | 1,350 | 1,295 | 825 | 757 | 829 |
| Total Assets | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,293 |
Below is a detailed analysis of the balance sheet data for Solara Active Pharma Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 44.00 Cr.. The value appears strong and on an upward trend. It has increased from 40.00 Cr. (Mar 2025) to 44.00 Cr., marking an increase of 4.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,210.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,054.00 Cr. (Mar 2025) to 1,210.00 Cr., marking an increase of 156.00 Cr..
- For Borrowings, as of Sep 2025, the value is 646.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 796.00 Cr. (Mar 2025) to 646.00 Cr., marking a decrease of 150.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 393.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 342.00 Cr. (Mar 2025) to 393.00 Cr., marking an increase of 51.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,293.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,232.00 Cr. (Mar 2025) to 2,293.00 Cr., marking an increase of 61.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,232.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,193.00 Cr. (Mar 2025) to 1,232.00 Cr., marking an increase of 39.00 Cr..
- For CWIP, as of Sep 2025, the value is 230.00 Cr.. The value appears to be declining and may need further review. It has decreased from 280.00 Cr. (Mar 2025) to 230.00 Cr., marking a decrease of 50.00 Cr..
- For Investments, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Other Assets, as of Sep 2025, the value is 829.00 Cr.. The value appears strong and on an upward trend. It has increased from 757.00 Cr. (Mar 2025) to 829.00 Cr., marking an increase of 72.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,293.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,232.00 Cr. (Mar 2025) to 2,293.00 Cr., marking an increase of 61.00 Cr..
Notably, the Reserves (1,210.00 Cr.) exceed the Borrowings (646.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -576.00 | -325.00 | -462.00 | -235.00 | 80.00 | 133.00 | -96.00 | -590.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 184 | 76 | 63 | 109 | 141 | 136 | 99 | 93 |
| Inventory Days | 252 | 111 | 170 | 149 | 321 | 258 | 163 | 185 |
| Days Payable | 420 | 127 | 132 | 156 | 154 | 142 | 142 | 145 |
| Cash Conversion Cycle | 16 | 60 | 101 | 102 | 308 | 252 | 120 | 133 |
| Working Capital Days | -124 | -22 | -32 | 16 | 37 | 20 | -128 | -62 |
| ROCE % | 10% | 12% | 15% | -0% | 2% | -9% | 6% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Aditya Birla Sun Life Flexi Cap Fund | 420,000 | 0.09 | 21.6 | 420,000 | 2025-04-22 17:25:20 | 0% |
| Aditya Birla Sun Life Manufacturing Equity Fund | 146,107 | 0.68 | 7.51 | 65,000 | 2025-08-29 00:02:49 | 124.78% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.14 | -157.62 | -6.16 | -16.18 | 69.00 |
| Diluted EPS (Rs.) | 0.14 | -157.62 | -6.16 | -16.18 | 64.53 |
| Cash EPS (Rs.) | 24.79 | -128.79 | 24.70 | 15.01 | 91.87 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 271.86 | 260.16 | 417.35 | 424.22 | 443.42 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 271.86 | 260.16 | 417.35 | 424.22 | 443.42 |
| Revenue From Operations / Share (Rs.) | 318.95 | 358.03 | 401.06 | 352.32 | 450.13 |
| PBDIT / Share (Rs.) | 53.32 | -24.95 | 43.45 | 27.77 | 115.43 |
| PBIT / Share (Rs.) | 28.66 | -53.65 | 12.57 | -3.42 | 85.18 |
| PBT / Share (Rs.) | 0.13 | -135.67 | -12.45 | -25.31 | 61.66 |
| Net Profit / Share (Rs.) | 0.13 | -157.49 | -6.18 | -16.19 | 61.62 |
| NP After MI And SOA / Share (Rs.) | 0.13 | -157.61 | -6.16 | -16.15 | 61.64 |
| PBDIT Margin (%) | 16.71 | -6.96 | 10.83 | 7.88 | 25.64 |
| PBIT Margin (%) | 8.98 | -14.98 | 3.13 | -0.97 | 18.92 |
| PBT Margin (%) | 0.04 | -37.89 | -3.10 | -7.18 | 13.69 |
| Net Profit Margin (%) | 0.04 | -43.98 | -1.54 | -4.59 | 13.68 |
| NP After MI And SOA Margin (%) | 0.04 | -44.02 | -1.53 | -4.58 | 13.69 |
| Return on Networth / Equity (%) | 0.04 | -60.75 | -1.47 | -3.81 | 13.93 |
| Return on Capital Employeed (%) | 8.95 | -17.42 | 2.51 | -0.65 | 16.76 |
| Return On Assets (%) | 0.02 | -24.13 | -0.76 | -1.96 | 8.47 |
| Long Term Debt / Equity (X) | 0.10 | 0.11 | 0.15 | 0.18 | 0.09 |
| Total Debt / Equity (X) | 0.70 | 1.07 | 0.66 | 0.67 | 0.32 |
| Asset Turnover Ratio (%) | 0.56 | 0.49 | 0.49 | 0.45 | 0.67 |
| Current Ratio (X) | 0.77 | 0.64 | 1.08 | 1.16 | 1.34 |
| Quick Ratio (X) | 0.43 | 0.35 | 0.57 | 0.61 | 0.96 |
| Inventory Turnover Ratio (X) | 3.79 | 1.66 | 1.37 | 1.97 | 2.38 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | -18.53 | 8.90 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 19.90 | 5.97 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 118.53 | 91.10 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 80.10 | 94.03 |
| Interest Coverage Ratio (X) | 1.87 | -0.85 | 1.74 | 1.33 | 4.91 |
| Interest Coverage Ratio (Post Tax) (X) | 1.00 | -2.58 | 0.75 | 0.27 | 3.62 |
| Enterprise Value (Cr.) | 2838.24 | 2334.27 | 2176.74 | 3374.17 | 5329.56 |
| EV / Net Operating Revenue (X) | 2.21 | 1.81 | 1.51 | 2.66 | 3.30 |
| EV / EBITDA (X) | 13.23 | -25.99 | 13.92 | 33.74 | 12.85 |
| MarketCap / Net Operating Revenue (X) | 1.61 | 1.04 | 0.81 | 1.89 | 3.10 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 118.53 | 91.09 |
| Price / BV (X) | 1.89 | 1.44 | 0.78 | 1.57 | 3.15 |
| Price / Net Operating Revenue (X) | 1.61 | 1.04 | 0.81 | 1.89 | 3.10 |
| EarningsYield | 0.00 | -0.42 | -0.01 | -0.02 | 0.04 |
After reviewing the key financial ratios for Solara Active Pharma Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 5. It has increased from -157.62 (Mar 24) to 0.14, marking an increase of 157.76.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 5. It has increased from -157.62 (Mar 24) to 0.14, marking an increase of 157.76.
- For Cash EPS (Rs.), as of Mar 25, the value is 24.79. This value is within the healthy range. It has increased from -128.79 (Mar 24) to 24.79, marking an increase of 153.58.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 271.86. It has increased from 260.16 (Mar 24) to 271.86, marking an increase of 11.70.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 271.86. It has increased from 260.16 (Mar 24) to 271.86, marking an increase of 11.70.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 318.95. It has decreased from 358.03 (Mar 24) to 318.95, marking a decrease of 39.08.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 53.32. This value is within the healthy range. It has increased from -24.95 (Mar 24) to 53.32, marking an increase of 78.27.
- For PBIT / Share (Rs.), as of Mar 25, the value is 28.66. This value is within the healthy range. It has increased from -53.65 (Mar 24) to 28.66, marking an increase of 82.31.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.13. This value is within the healthy range. It has increased from -135.67 (Mar 24) to 0.13, marking an increase of 135.80.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 2. It has increased from -157.49 (Mar 24) to 0.13, marking an increase of 157.62.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 2. It has increased from -157.61 (Mar 24) to 0.13, marking an increase of 157.74.
- For PBDIT Margin (%), as of Mar 25, the value is 16.71. This value is within the healthy range. It has increased from -6.96 (Mar 24) to 16.71, marking an increase of 23.67.
- For PBIT Margin (%), as of Mar 25, the value is 8.98. This value is below the healthy minimum of 10. It has increased from -14.98 (Mar 24) to 8.98, marking an increase of 23.96.
- For PBT Margin (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 10. It has increased from -37.89 (Mar 24) to 0.04, marking an increase of 37.93.
- For Net Profit Margin (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from -43.98 (Mar 24) to 0.04, marking an increase of 44.02.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 8. It has increased from -44.02 (Mar 24) to 0.04, marking an increase of 44.06.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 15. It has increased from -60.75 (Mar 24) to 0.04, marking an increase of 60.79.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.95. This value is below the healthy minimum of 10. It has increased from -17.42 (Mar 24) to 8.95, marking an increase of 26.37.
- For Return On Assets (%), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -24.13 (Mar 24) to 0.02, marking an increase of 24.15.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 0.2. It has decreased from 0.11 (Mar 24) to 0.10, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.70. This value is within the healthy range. It has decreased from 1.07 (Mar 24) to 0.70, marking a decrease of 0.37.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has increased from 0.49 (Mar 24) to 0.56, marking an increase of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1.5. It has increased from 0.64 (Mar 24) to 0.77, marking an increase of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has increased from 0.35 (Mar 24) to 0.43, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.79. This value is below the healthy minimum of 4. It has increased from 1.66 (Mar 24) to 3.79, marking an increase of 2.13.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.87. This value is below the healthy minimum of 3. It has increased from -0.85 (Mar 24) to 1.87, marking an increase of 2.72.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.00. This value is below the healthy minimum of 3. It has increased from -2.58 (Mar 24) to 1.00, marking an increase of 3.58.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,838.24. It has increased from 2,334.27 (Mar 24) to 2,838.24, marking an increase of 503.97.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.21. This value is within the healthy range. It has increased from 1.81 (Mar 24) to 2.21, marking an increase of 0.40.
- For EV / EBITDA (X), as of Mar 25, the value is 13.23. This value is within the healthy range. It has increased from -25.99 (Mar 24) to 13.23, marking an increase of 39.22.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has increased from 1.04 (Mar 24) to 1.61, marking an increase of 0.57.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 1.44 (Mar 24) to 1.89, marking an increase of 0.45.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has increased from 1.04 (Mar 24) to 1.61, marking an increase of 0.57.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.42 (Mar 24) to 0.00, marking an increase of 0.42.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Solara Active Pharma Sciences Ltd:
- Net Profit Margin: 0.04%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.95% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.04% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.43
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 386 (Industry average Stock P/E: 52.62)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.7
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.04%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | �Cyber One�, Unit No. 902, Plot No. 4 & 6, Sector 30A, New Mumbai Maharashtra 400703 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. R Ramakrishnan | Chairperson & Independent Director |
| Mr. Sandeep Shashikantha Rao | Managing Director & CEO |
| Mr. Mohan Muthunarayanan | Whole Time Director & COO |
| Mr. Manish Gupta | Non Executive Director |
| Mr. Kartheek Chintalapati Raju | Non Executive Director |
| Mr. Arun Kumar Pillai | Non Executive Director |
| Dr. Kausalya Santhanam | Independent Director |
| Mr. Rajiv Vijay Nabar | Independent Director |
| Mr. Rajendra Kumar Srivastava | Independent Director |
FAQ
What is the intrinsic value of Solara Active Pharma Sciences Ltd?
Solara Active Pharma Sciences Ltd's intrinsic value (as of 15 January 2026) is ₹54.65 which is 90.19% lower the current market price of ₹557.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹2,475 Cr. market cap, FY2025-2026 high/low of ₹734/441, reserves of ₹1,210 Cr, and liabilities of ₹2,293 Cr.
What is the Market Cap of Solara Active Pharma Sciences Ltd?
The Market Cap of Solara Active Pharma Sciences Ltd is 2,475 Cr..
What is the current Stock Price of Solara Active Pharma Sciences Ltd as on 15 January 2026?
The current stock price of Solara Active Pharma Sciences Ltd as on 15 January 2026 is ₹557.
What is the High / Low of Solara Active Pharma Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Solara Active Pharma Sciences Ltd stocks is ₹734/441.
What is the Stock P/E of Solara Active Pharma Sciences Ltd?
The Stock P/E of Solara Active Pharma Sciences Ltd is 386.
What is the Book Value of Solara Active Pharma Sciences Ltd?
The Book Value of Solara Active Pharma Sciences Ltd is 347.
What is the Dividend Yield of Solara Active Pharma Sciences Ltd?
The Dividend Yield of Solara Active Pharma Sciences Ltd is 0.00 %.
What is the ROCE of Solara Active Pharma Sciences Ltd?
The ROCE of Solara Active Pharma Sciences Ltd is 6.01 %.
What is the ROE of Solara Active Pharma Sciences Ltd?
The ROE of Solara Active Pharma Sciences Ltd is 0.05 %.
What is the Face Value of Solara Active Pharma Sciences Ltd?
The Face Value of Solara Active Pharma Sciences Ltd is 10.0.